Issue 06

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

Today, we’re delighted to launch The Psychedelics as Medicine Report: Second Edition. Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.

The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase.

The report contains:

– Proprietary consumer insights on attitudes, uses and behaviours
– Deep dives into the most transformative compounds and companies
– Key regulations, transformative trends and commercial opportunities

Download your free copy now.

BUSINESS AND INVESTMENT


COMPASS Pathways stock reaches $1 billion after debut IPO.


HAVN Life announces listing approval on the Frankfurt Stock Exchange.


Bexson Biomedical and Stevanato collaborate to develop wearable ketamine device.


Mind Cure announces commencement of trading on the CSE.


AWAKN launches psychedelic clinical research division in Europe and North America.


GreenStar announces patent application for psilocybin VR administration device.


MindMed submits an application for NASDAQ up-listing to expand its investor base.


Societal impact of legalising psychedleic medicines weighed-up.


Mydecine completes acquisition of psychedelic-based treatment-provider NeuroPharm.


Red Light Holland announces arrangement with McSmart to launch microdosing packs.


Revive plans clinical trial of psilocybin therapy for methamphetamine addiction.

REGULATION AND LEGISLATION


New poll finds three in five DC voters support the decriminalisation of psychedelic plants.


Veteran groups in Oregon support the legalisation of psilocybin therapy.


NICE rejects esketamine spray, Spravato, for treatment-resistant depression.


Ann Arbor city council considers decriminalising entheogenic substances.

RESEARCH AND SCIENCE


UC Berkeley launches new centre for psychedelic science and education.


Australian hospital is working on two clinical psilocybin trials to treat mental health.


MDMA-assisted treatment for PTSD has reached Phase 3 clinical trial stage.


New study suggests psychedelics may decrease depression and suicidal thoughts.


Brazilian researchers study psychedelics to treat depression and drug abuse.